Cargando...
Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
AIM: To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status. METHODS: Safety data from 14 trials (8–104‐week durations) were analysed by treatment (alirocumab or placebo/ezetimibe control) and diabetes status (ye...
Gardado en:
| Publicado en: | Diabet Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6585811/ https://ncbi.nlm.nih.gov/pubmed/30183102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dme.13817 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|